We are live on ! Find out more
SCM

Suvretta Capital Management Portfolio holdings

AUM $3.92B
1-Year Est. Return 86.67%
This Fund
S&P 500
This Quarter Est. Return
-5.35%
1 Year Est. Return
+86.67%
3 Year Est. Return
+295.96%
5 Year Est. Return
+364.48%
10 Year Est. Return
+2,073.65%
AUM
$2.69B
AUM Growth
-$239M
Cap. Flow
+$33.3M
Cap. Flow %
1.24%
Top 10 Hldgs %
47.52%
Holding
112
New
16
Increased
29
Reduced
14
Closed
12

Top Buys

Rank Stock Value
1
HD icon
Home Depot
HD
+$38M
2
RARE icon
Ultragenyx Pharmaceutical
RARE
+$36.3M
3
ETNB
89bio
ETNB
+$36.1M
4
BAC icon
Bank of America
BAC
+$33.6M
5
CMG icon
Chipotle Mexican Grill
CMG
+$29.3M

Top Sells

Rank Stock Value
1
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$92M
2
KO icon
Coca-Cola
KO
+$48.2M
3
SBUX icon
Starbucks
SBUX
+$47M
4
CRH icon
CRH
CRH
+$41.5M
5
MCD icon
McDonald's
MCD
+$30M

Sector Composition

Rank Sector Weight
1 Healthcare 60.02%
2 Technology 10.47%
3 Consumer Discretionary 6.61%
4 Financials 5.33%
5 Communication Services 4.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$778B
$224M 8.3%
400,000
+50,000
+14% +$29.4M
ARQT icon
2
Arcutis Biotherapeutics
ARQT
$3.42B
$179M 6.63%
11,422,978
+23,840
+0.2% +$336K
BHVN icon
3
Biohaven
BHVN
$2.16B
$135M 5.01%
5,620,271
– –
BNTC icon
4
Benitec Biopharma
BNTC
$394M
$128M 4.77%
9,876,506
+916,497
+10% +$11.1M
LEGN icon
5
Legend Biotech
LEGN
$4.3B
$127M 4.72%
3,749,965
+253,731
+7% +$9.1M
INSM icon
6
Insmed
INSM
$23.2B
$114M 4.22%
1,492,383
-119,178
-7% -$9.12M
ETNB
7
DELISTED
89bio
ETNB
$104M 3.87%
14,335,244
+4,132,548
+41% +$36.1M
META icon
8
Meta Platforms (Facebook)
META
$1.51T
$104M 3.84%
179,664
+9,326
+5% +$6.02M
ITCI
9
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$92.5M 3.43%
700,904
-738,122
-51% -$92M
RARE icon
10
Ultragenyx Pharmaceutical
RARE
$2.65B
$73.3M 2.72%
2,024,500
+873,186
+76% +$36.3M
MSFT icon
11
Microsoft
MSFT
$2.84T
$67.6M 2.51%
180,125
+61,728
+52% +$25.2M
AMZN icon
12
Amazon
AMZN
$2.5T
$67.4M 2.5%
354,356
+3,075
+0.9% +$667K
TSM icon
13
TSMC
TSM
$2.09T
$58.2M 2.16%
350,514
+4,602
+1% +$894K
KALV
14
DELISTED
KalVista Pharmaceuticals
KALV
$56.7M 2.1%
4,913,012
– –
APO icon
15
Apollo Global Management
APO
$70.7B
$54.3M 2.02%
396,540
-67,600
-15% -$10.4M
KURA icon
16
Kura Oncology
KURA
$922M
$49.1M 1.82%
7,439,259
+2,362,811
+47% +$18.4M
COF icon
17
Capital One
COF
$124B
$44M 1.63%
245,222
-6,420
-3% -$1.21M
AVBP icon
18
ArriVent BioPharma
AVBP
$1.48B
$43.2M 1.6%
2,337,496
+91,496
+4% +$2.24M
AMD icon
19
Advanced Micro Devices
AMD
$851B
$41.5M 1.54%
404,008
+66,593
+20% +$7.4M
IMTX icon
20
Immatics
IMTX
$1.24B
$41.2M 1.53%
9,135,029
+4,069,752
+80% +$21.2M
GE icon
21
GE Aerospace
GE
$367B
$40.2M 1.49%
200,662
– –
NVDA icon
22
NVIDIA
NVDA
$5.01T
$38.2M 1.42%
352,765
+172,009
+95% +$21.8M
EYPT icon
23
EyePoint Inc
EYPT
$1.02B
$36.9M 1.37%
6,804,091
+21,000
+0.3% +$147K
APLS
24
DELISTED
Apellis Pharmaceuticals
APLS
$36M 1.34%
1,646,615
+853,428
+108% +$23.6M
HD icon
25
Home Depot
HD
$332B
$35.8M 1.33%
+97,571
New +$38M
1
2 3 4 5

Similar funds

MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
AA
Alesco Advisors Pittsford, New York $3.92B AUM 15.21% 1-Year Est. Return
CCM
Channing Capital Management Chicago, Illinois $3.91B AUM 34.32% 1-Year Est. Return
BCP
BSN Capital Partners London, United Kingdom $3.93B AUM 13.09% 1-Year Est. Return
AS
American Securities New York $3.93B AUM 52.22% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
LWCA
Locust Wood Capital Advisers New York $3.95B AUM 33.1% 1-Year Est. Return

Suvretta Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, Suvretta Capital Management held 112 positions worth $2.69B, down 8.2% from $2.93B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Suvretta Capital Management's Q1 2025 filing shows 16 new, 29 increased, 14 reduced and 12 closed positions. Its largest new stake was Home Depot: 97,571 shares worth $35.8M. The largest sale was Intra-Cellular Therapies Inc., an estimated $92M.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, up from 56% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Suvretta Capital Management's largest Q1 2025 buy was Home Depot: 97,571 shares worth $35.8M.
  • Suvretta Capital Management added most to Ultragenyx Pharmaceutical in Q1 2025, an estimated $36.3M increase.
  • Suvretta Capital Management's biggest Q1 2025 reduction was Intra-Cellular Therapies Inc., cutting an estimated $92M.
  • Suvretta Capital Management fully exited Starbucks in Q1 2025, selling an estimated $47M.
  • Suvretta Capital Management's ten largest holdings make up 48% of its $2.69B portfolio in Q1 2025.
  • Suvretta Capital Management opened 16 new positions and closed 12 in Q1 2025.
  • Suvretta Capital Management's portfolio value fell 8.2% quarter-over-quarter to $2.69B.

Based on Suvretta Capital Management's 13F filing for Q1 2025, filed 15 May 2025.